Nabriva Therapeutics plc – Ordinary Shares (NASDAQ:NBRV) shares are shooting up faster than the speed of light at a 44% surge after the drug maker’s Phase 3 study investigating IV and oral lefamulin in CABP achieved the primary endpoints for both the FDA as well as the EMA.
Cantor analyst Louise Chen says for anyone who thought he was leaping to bullish conclusions, the proof is in the pudding: Nabriva’s LEAP 1 data is positive, and the Street is out celebrating the firm’s lead asset’s exciting potential today.
As such, the analyst reiterates an Overweight rating on shares of NBRV with a $16 price target, which implies a just under 62% upside from where the stock is currently trading. (To watch Chen’s track record, click here)
“We think that lefamulin has a meaningful opportunity for use in the treatment of hospital-initiated adult CABP. This is because current treatment options (fluoroquinolones and beta-lactam+ macrolide) have limitations, however lefamulin could garner significant usage due to a number of factors including its: 1) Targeted spectrum of activity, 2) Short course monotherapy, 3) Flexible dosing (IV and oral step down), and 4) Low propensity for resistance to develop,” Chen underscores.
Glancing ahead to compelling commercial prospects, this clinical stride glimmers for Nabriva, as the analyst contends, “The data reinforces our positive outlook for lefamulin’s peak sales potential, with data from the second Phase 3 trial expected in Spring of ’18. We see a positive read through from the LEAP 1 data to LEAP 2 data in ’18. In LEAP 1 (with IV and oral) a significant number of patients received the oral product and these results were positive. In our view, Nabriva has great PK/PD data on the oral as well.”
Analyst consensus is quite confident on this drug maker, as TipRanks analytics demonstrate NBRV as a Strong Buy. Out of 3 analysts polled by TipRanks in the last 3 months, all 3 are bullish on Nabriva stock. With a return potential of 83%, the stock’s consensus target price stands at $16.33.